With Pantherna’s LNP technology, we’re pioneering the next generation of mRNA therapeutics. Our dual-platform approach, combining PTXmRNA® and PTXΔLNP®, allows for custimized, tissue-targeted mRNA expression. Crucially, we’re leveraging the power of surface charge manipulation to generate novel PTXΔLNP® formulations, enabling us to fine-tune RNA delivery to specific tissues and cell types (beyond the liver).
We engineer PTXmRNA® for transient protein expression, adaptable to various delivery methods. Our PAN004 program exemplifies this, utilizing LNP002 to selectively target the lung endothelium via intravenous administration. We’re also developing diverse PTXΔLNP® formulations, partnering with academic pioneers to explore their therapeutic potential across a wide range of diseases. With a focus on high unmet medical needs, including rare conditions, we’re dedicated to unlocking the transformative power of mRNA.
Precise delivery with surface charge control
Tissue-specific PTXΔLNP® formulations
Pantherna’s LNP technology provides precise, versatile delivery of nucleic acid cargos (e.g., mRNA) by customizing LNPs to overcome the liver tropism of standard formulations. This is achieved through tailored lipid compositions with surface charge control—anionic, neutral, or cationic—and the incorporation of targeting conjugates such as antibodies, creating optimized non-viral vectors for various tissues and administration routes. This scalable platform, with candidate formulations in development, is protected by strong IP and complements our PTXmRNA® technology, placing us at the forefront of genetic medicine.
Local delivery for local activity
PTXΔLNP® target tissues
Pantherna’s strategy for advancing its PTXΔLNP delivery systems to unlock commercial partnerships, illustratrating various therapeutic areas and target organs. Pantherna aims to become a leading provider of ready-to-go LNP vector solutions poised for clinical translation of new first-in-class medicines to the pharmaceutical industry.
Amuse-Gueules
Selected PTXΔLNP® formulations
Ensuring top level protein expression
PTXmRNA®
Pantherna’s PTXmRNA® platform features uniquely tailored UTRs and optional secretion signals, driving potent tissue-specific protein expression. Leveraging advanced modifications for minimized immune activation, this IP-protected technology sets a new standard in mRNA therapeutics and fosters strategic partnerships.